Table 3.
Summary of efficacy outcomes in the subgroup of patients with comorbidities at week 16 (N = 57)
| Outcome | Baseline | Week 16 | P-value* |
|---|---|---|---|
| Perennial allergic rhinitis n = 31 | |||
| RCSS score | |||
| Median ± IQR | 24.0 ± 13.0 | 16.0 ± 7.5 | < 0.001 |
| RQLQ score | |||
| Median ± IQR | 3.8 ± 1.1 | 2.0 ± 1.4 | < 0.001 |
| Bronchial asthma n = 46 | |||
| FEV1 (L) before bronchodilation-liters | |||
| Median ± IQR | 2.7 ± 0.8 | 2.8 ± 0.9 | < 0.001 |
| Missing, n (%) | 2 (4.3) | 2 (4.3) | |
| FEV1% of predicted | |||
| Median ± IQR | 90.5 ± 15.3 | 96.5 ± 11.5 | < 0.001 |
| Missing, n (%) | 2 (4.3) | 2 (4.3) | |
| ACT score | |||
| Median ± IQR | 18.0 ± 6.8 | 24.0 ± 5.0 | < 0.001 |
| AQLQ (S) score | |||
| Median ± IQR | 4.3 ± 2.8 | 6.0 ± 1.3 | < 0.001 |
| Atopic dermatitis n = 10 | |||
| EASI score | |||
| Median ± IQR | 34.2 ± 20.0 | 4.3 ± 1.4 | < 0.01 |
| Peak score on NRS for pruritus | |||
| Median ± IQR | 8.5 ± 1.0 | 3.0 ± 1.0 | < 0.01 |
| Peak score on NRS for sleep | |||
| Median ± IQR | 8.0 ± 0.8 | 1.5 ± 2.5 | < 0.01 |
| DLQI score | |||
| Median ± IQR | 24.0 ± 12.5 | 4.0 ± 1.8 | < 0.01 |
| Chronic spontaneous urticaria n = 3 | |||
| UAS7 score | |||
| Median ± IQR | 12.0 ± 4.0 | 0 ± 5.0 | > 0.05 |
ACT, Asthma Control Test; AD, Atopic Dermatitis; AQLQ (S), Asthma Quality of Life Questionnaire (standardized version); DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; FEV1, Forced Expiratory Volume in 1 s; IQR, Interquartile Range; NRS, Numerical Rating Scale; RCSS, Rhinitis Control Scoring System; RQLQ, Rhinitis Quality of Life Questionnaire; UAS7, Urticaria Activity Score;
*Compared using the Wilcoxon test for paired data. The threshold for statistical significance was set at P < 0.01